Vitamin D3 Deficiency: Treatment Guidelines (2024-2025)

Definitions and Diagnostic Thresholds

2024 Endocrine Society Clinical Practice Guideline - Key Shifts

• Suggests empiric supplementation (above DRI) for:
  • Children and adolescents 1-18 years (respiratory tract infections, rickets prevention)
  • Adults ≥75 years (reduced mortality)
  • Pregnant women (reduce preeclampsia, preterm birth, intrauterine mortality)
  • High-risk prediabetes (slow progression to type 2 diabetes)
• Recommends daily dosing (not intermittent high-dose boluses) for non-pregnant adults over 50 requiring supplementation
• Recommends against empiric supplementation above DRI in healthy adults under 75
• Recommends against routine 25(OH)D testing in the general population

Note: This 2024 guideline covers disease prevention in healthy people. For treatment of established deficiency, the 2011 Endocrine Society guidelines remain the core clinical reference.

Treatment of Established Vitamin D Deficiency: Endocrine Society Dosing Table

• Both cholecalciferol (D3) and ergocalciferol (D2) are acceptable, but D3 is preferred - D2 is only ~30% as effective at maintaining 25(OH)D levels (Yamada's Gastroenterology; Goodman & Gilman's notes D3 has ~10x greater potency than D2)
• Target level: ≥30 ng/mL (>75 nmol/L) per Endocrine Society; ≥20 ng/mL per NAM

Harrison's Principles (22E, 2025) on Treatment

• The National Academy of Medicine recommends 600 IU/day (ages 1-70) and 800 IU/day (>70 years) for prevention
• The VITAL trial showed supraphysiological doses in adults with normal vitamin D levels do NOT improve bone mineral density, skeletal microarchitecture, or prevent falls
• Large intermittent bolus doses of vitamin D3 can paradoxically increase fractures and falls in older adults - daily small doses (e.g., 400-800 IU) are safer
• Monitoring: urinary calcium excretion and serum calcium are the most effective markers to monitor treatment success. Target 24-hour urinary calcium: 100-300 mg/day in replete patients

Special Populations and Indications

Infants (<1 year)

• 400-1,000 IU/day recommended, especially breast-fed infants (2011 Endocrine Society; note: the 2024 guideline did not address this group)

Pregnancy

• ACOG recommends testing women at increased risk; 1,000-2,000 IU/day if deficient - Creasy & Resnik's Maternal-Fetal Medicine
• The 2024 Endocrine Society guideline suggests empiric supplementation to reduce preeclampsia and preterm birth risk

Chronic Kidney Disease

• In CKD, standard nutritional vitamin D (cholecalciferol/ergocalciferol) should be used to correct 25(OH)D to targets recommended for the general population. Active vitamin D analogues (calcitriol, paricalcitol, alfacalcidol) are used specifically for managing secondary hyperparathyroidism and are not interchangeable with nutritional vitamin D - National Kidney Foundation Primer, 8e

Malabsorption (e.g., IBD, cystic fibrosis, post-bariatric)

• Require significantly higher doses (2-3x standard), titrated by serum levels
• In Crohn's disease: initiate at 1,000 IU/day and escalate up to 5,000 IU/day targeting 25(OH)D ≥40 ng/mL - Yamada's Gastroenterology, 7e

Drugs Affecting Vitamin D Metabolism

• Anticonvulsants (phenytoin, carbamazepine), glucocorticoids, and drugs activating the steroid xenobiotic receptor accelerate 25(OH)D catabolism - use higher-dose regimens (obese adult tier)

Vitamin D Toxicity

• Wide safety margin: toxicity is rare and requires very high doses (typically >10,000 IU/day for prolonged periods, or massive single doses >100,000 IU)
• Toxicity manifests as hypercalcemia, hypercalciuria, nausea, renal calculi, and soft tissue calcification
• Maintaining levels above 50 ng/mL does not appear to confer additional benefit and may not be necessary for most patients (2024 Endocrine Society guideline)

Summary of Current Guidance Consensus (2025)

1. No screening or empiric supplementation for healthy general adults without risk factors
2. Screening and treatment for high-risk groups
3. Supplementation doses of 400-1,000 IU/day for elderly populations and those with osteoporosis
4. Minimum target 25(OH)D threshold of 50-75 nmol/L (20-30 ng/mL) across most guidelines
5. Considerable variability exists between guidelines on definitions of "at risk" and optimal target levels - no single international consensus yet

• Demay et al. (2024). Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 109(8):1907-1947. (PMID 38828931)
• Zemp et al. (2025). Systematic review of evidence-based clinical guidelines for vitamin D screening and supplementation. Archives of Public Health. (PMID 40883815)
• Harrison's Principles of Internal Medicine, 22E (2025, McGraw Hill), p. 3314
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry (Table 30.5-1, Endocrine Society Guidelines)
• National Kidney Foundation Primer on Kidney Diseases, 8e